Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
86
Recruiting, any sponsor type, condition "migraine"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed618
86 trials
Showing 1 to 25, recently updated first.
PfizerPfizer (PFE)
NCT07609914 · 400 participants (planned) · Start May 28, 2026 · Primary completion Jun 7, 2028
Drug: Rimegepant · For: Acute Treatment of Migraine
Sites: Canoga Park, California; Fresno, California; Los Angeles, California · 38 sites in all
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigrainePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07729462 · 400 participants (planned) · Start Aug 26, 2026 · Primary completion Oct 21, 2028
Drug: Rimegepant; Placebo · For: Preventive Treatment of Migraine
Sites: Scottsdale, Arizona; Canoga Park, California; Fresno, California · 38 sites in all
PfizerPfizer (PFE)
NCT07685769 · 60 participants (planned) · Start Jul 24, 2026 · Primary completion Jan 4, 2028
Drug: Rimegepant 75 mg ODT · For: Acute Treatment of Migraine
Sites: Visakhapatnam, India; Gurugram, India; Bangalore, India · 7 sites in all
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05156398 · 640 participants (planned) · Start Feb 28, 2022 · Primary completion Mar 27, 2029
Drug: Rimegepant; Placebo · For: Migraine
Sites: Fort Smith, Arkansas; Hawthorne, California; La Mesa, California · 97 sites in all
University of South FloridaAcademic, hospital or other
NCT07667621 · 100 participants (planned) · Start Sep 15, 2026 · Primary completion Jul 2027
Drug: Rimegepant; Zavegepant · For: Migraine; Migraine Disease; Migraine in Adults and 4 more
Sites: Tampa, Florida
- Study of EVO756 in Adults With MigrainePivotal-lookingRecruiting
Evommune, Inc.Industry
NCT07616128 · 330 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2027
Drug: EVO756, Dose 1; EVO756, Dose 2 and 1 more · For: Migraine
Sites: Chandler, Arizona; Buena Park, California; Fresno, California · 45 sites in all
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06972056 · 1,335 participants (planned) · Start Jul 9, 2025 · Primary completion Mar 1, 2029
Drug: Atogepant 60 mg; Propranolol 160 mg and 1 more · For: Migraine
Sites: Hazel Green, Alabama; Flagstaff, Arizona; Phoenix, Arizona · 39 sites in all
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07816367 · 1,500 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 2027
Drug: Elismetrep; Placebo · For: Migraine
Sites: Glendale, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 72 sites in all
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsPivotal-lookingRecruiting
Brise Pharmaceuticals Co., Ltd.Industry
NCT07792681 · 2,079 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: BR005-036C; BR005-036C and 1 more · For: Migraine, With or Without Aura
Sites: Shanxi, China; Inner Mongolia, China; Beijing, China · 81 sites in all
IRCCS San RaffaeleAcademic, hospital or other
NCT05907655 · 50 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 30, 2027
Drug: Nitroglycerin 0.3 MG · For: Migraine
Sites: Milan, Italy
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07645924 · 1,800 participants (planned) · Start Jul 1, 2026 · Primary completion Feb 2027
Drug: Elismetrep; Placebo · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 113 sites in all
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07674654 · 1,000 participants (planned) · Start Aug 3, 2026 · Primary completion Jun 2028
Drug: Elismetrep · For: Acute Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 113 sites in all
- Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Pivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT07191145 · 80 participants (planned) · Start Nov 2026 · Primary completion Jun 30, 2027
Drug: Eptinezumab · For: Post Traumatic Headache
Sites: Toronto, Canada
- Randomized Study in Children and Adolescents With Migraine: Acute TreatmentPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT04649242 · 2,100 participants (planned) · Start Jan 15, 2021 · Primary completion Jan 9, 2029
Drug: Rimegepant/BHV3000; Matching placebo · For: Pediatric Migraine
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tempe, Arizona · 246 sites in all
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigrainePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT04743141 · 600 participants (planned) · Start Apr 28, 2021 · Primary completion Jul 31, 2030
Drug: Rimegepant (PF-07899801) · For: Acute Treatment of Migraine
Sites: Scottsdale, Arizona; Tempe, Arizona; Anaheim, California · 124 sites in all
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigrainePivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT04965675 · 285 participants (planned) · Start Jun 30, 2021 · Primary completion Mar 26, 2027
Drug: Eptinezumab; Placebo · For: Chronic Migraine in Children
Sites: New Haven, Connecticut; Stamford, Connecticut; Washington D.C., District of Columbia · 79 sites in all
- A Study of Eptinezumab in Pediatric Participants With Episodic MigrainePivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT05897320 · 315 participants (planned) · Start Jun 8, 2023 · Primary completion Jul 6, 2027
Drug: Eptinezumab; Placebo · For: Episodic Migraine
Sites: Stamford, Connecticut; Gulf Breeze, Florida; Hialeah, Florida · 60 sites in all
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT07067112 · 24 participants (planned) · Start Sep 10, 2026 · Primary completion Nov 30, 2027
Drug: Blood sampling, questionnaire and phone call · For: Chronic Migraine
Sites: Clermont-Ferrand, France
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigrainePivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT05164172 · 600 participants (planned) · Start Dec 1, 2021 · Primary completion Apr 30, 2028
Drug: Eptinezumab · For: Migraine
Sites: New Haven, Connecticut; Stamford, Connecticut; Gainesville, Florida · 64 sites in all
Wensheng QuAcademic, hospital or other
NCT07871097 · 80 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 30, 2027
Drug: First dose rimegepant, second dose placebo; First dose placebo, second dose rimegepant · For: Vestibular Migraine
Sites: Wuhan, China
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06810505 · 420 participants (planned) · Start Feb 13, 2025 · Primary completion Mar 2031
Drug: Atogepant; Placebo for Atogepant · For: Chronic Migraine
Sites: Huntsville, Alabama; Fayetteville, Arkansas; Little Rock, Arkansas · 66 sites in all
- Migraine Headaches Elimination With Patent Foramen Ovale-Directed TherapyPivotal-lookingRecruiting
Columbia UniversityAcademic, hospital or other
NCT07629635 · 32 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 31, 2027
Drug: Prasugrel 5mg · For: Migraine Disease; Patent Foramen Ovale
Sites: New York, New York
- Greater Occipital Nerve Block for Migraine With Medication Overuse HeadachePivotal-lookingRecruiting
Mahidol UniversityAcademic, hospital or other
NCT07568496 · 130 participants (planned) · Start May 12, 2026 · Primary completion Nov 1, 2028
Drug: Lidocaine 2% and Methylprednisolone 80 mg · For: Migraine Disorders; Medication Overuse Headache; Greater Occipital Nerve Block
Sites: Bangkok, Thailand; Hat Yai, Thailand; Chiang Mai, Thailand
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigrainePivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT05711394 · 450 participants (planned) · Start May 1, 2023 · Primary completion Mar 2028
Drug: Atogepant; Placebo-Matching Atogepant · For: Episodic Migraine
Sites: Huntsville, Alabama; Saraland, Alabama; Little Rock, Arkansas · 98 sites in all
Daniel A Tonetti, MDAcademic, hospital or other
NCT07361549 · 80 participants (planned) · Start Sep 9, 2026 · Primary completion Dec 2030
Drug: Lidocaine (drug); Saline · For: Refractory Migraine; Headache
Sites: Camden, New Jersey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.